GSK reports Blenrep overall survival data in multiple myeloma as it plots market reentry

SAN DIEGO — Two years af­ter pulling Blenrep from the mar­ket, GSK is po­si­tion­ing for a re­launch.

This time, the com­pa­ny says it’s com­ing from a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.